Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 12/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3066044 | 0.90 | TRPM8 (0.47) | NOS3NOS1NOS2CYP3A4TRPM8 | |
| SCHEMBL3050876 | 0.89 | PDK1 (0.46) | NOS3NOS1NOS2CYP3A4TRPM8 | |
| SCHEMBL3052135 | 0.88 | TRPM8 (0.48) | NOS3NOS1NOS2TRPM8PDK1 | |
| SCHEMBL3049921 | 0.86 | TSPO (0.46) | NOS3NOS1NOS2ALDH1A1TP53 | |
| SCHEMBL3058597 | 0.85 | TACR1 (0.43) | CYP3A4TRPM8PDK1ALDH1A1MAPT | |
| SCHEMBL3064381 | 0.83 | RAB9A (0.49) | NOS3NOS1NOS2CYP3A4TRPM8 | |
| SCHEMBL3054727 | 0.82 | GAA (0.53) | PDK1ALDH1A1MAPTRAB9AGAA | |
| SCHEMBL3048580 | 0.82 | RAB9A (0.44) | NOS3NOS1NOS2TRPM8PDK1 | |
| SCHEMBL3177779 | 0.81 | TRPM8 (0.62) | TRPM8PDK1ALDH1A1MAPTTP53 | |
| SCHEMBL3044246 | 0.81 | RAB9A (0.57) | NOS3NOS1NOS2PDK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| CN-101405268-A | Amide derivatives and their use for the treatment of protein-related diseases | NOVARTIS AG (CH) | 2009-04-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | HRH4, CNR1, CNR2 | NOS3 3019/4885NOS1 3682/4885NOS2 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.